

# CITATION REPORT

List of articles citing

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis

DOI: 10.1093/hmg/ddl440

Human Molecular Genetics, 2007, 16, 61-77.

**Source:** <https://exaly.com/paper-pdf/41661041/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
233	In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 36736-43	5.4	54
232	Characterization, developmental expression and evolutionary features of the huntingtin gene in the amphioxus <i>Branchiostoma floridae</i> . <b>2007</b> , 7, 127		10
231	The structural impact of a polyglutamine tract is location-dependent. <b>2008</b> , 95, 5922-30		28
230	Huntington's disease: from pathology and genetics to potential therapies. <b>2008</b> , 412, 191-209		333
229	[Pathophysiology of Huntington's disease: an update]. <b>2008</b> , 164, 977-94		4
228	Golgi apparatus and neurodegenerative diseases. <b>2008</b> , 26, 523-34		74
227	Mutant huntingtin and mitochondrial dysfunction. <b>2008</b> , 31, 609-16		182
226	Impaired regulation of brain mitochondria by extramitochondrial Ca <sup>2+</sup> in transgenic Huntington disease rats. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 30715-24	5.4	68
225	Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. <b>2008</b> , 25, 330-8		65
224	N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. <b>2008</b> , 28, 2783-92		312
223	The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration. <b>2008</b> , 8, 157-72		113
222	Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 2390-404	5.6	102
221	Protective role of Engrailed in a <i>Drosophila</i> model of Huntington's disease. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 3601-16	5.6	21
220	Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. <b>2008</b> , 28, 9013-20		90
219	Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. <b>2008</b> , 21, 497-503		93
218	Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. <b>2009</b> , 9, 1189-97		25
217	Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 29427-36	5.4	122

216	Mitochondria and energetic depression in cell pathophysiology. <b>2009</b> , 10, 2252-303	62
215	IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. <b>2009</b> , 187, 1083-99	287
214	Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease. <b>2009</b> , 36, 374-83	58
213	Secondary structure of Huntingtin amino-terminal region. <b>2009</b> , 17, 1205-12	199
212	Mitochondrial structural and functional dynamics in Huntington's disease. <b>2009</b> , 61, 33-48	128
211	Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. <b>2009</b> , 16, 380-9	336
210	The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. <b>2009</b> , 16, 1279-85	191
209	The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. <b>2009</b> , 110, 1737-65	154
208	Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. <b>2009</b> , 64, 828-40	244
207	Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. <b>2009</b> , 40, 121-7	70
206	Neurotoxic protein oligomerisation associated with polyglutamine diseases. <b>2010</b> , 120, 419-37	62
205	Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. <b>2010</b> , 42, 217-26	25
204	The regulation of OXPHOS by extramitochondrial calcium. <b>2010</b> , 1797, 1018-27	79
203	Misfolding and Aggregation in Huntington Disease and Other Expanded Polyglutamine Repeat Diseases. <b>2010</b> , 305-324	3
202	Conformation sensors that distinguish monomeric proteins from oligomers in live cells. <b>2010</b> , 17, 371-9	35
201	Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. <b>2010</b> , 114, 1-12	110
200	Simple is good: yeast models of neurodegeneration. <b>2010</b> , 10, 970-9	65
199	Glutamate-induced alterations in Ca <sup>2+</sup> signaling are modulated by mitochondrial Ca <sup>2+</sup> handling capacity in brain slices of R6/1 transgenic mice. <b>2010</b> , 32, 60-70	25

198	Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. <i>Human Molecular Genetics</i> , <b>2010</b> , 19, 3190-205	5.6	108
197	Does Huntingtin play a role in selective macroautophagy?. <b>2010</b> , 9, 3401-13		59
196	Antibody therapy in neurodegenerative disease. <b>2010</b> , 21, 273-87		16
195	Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin. <b>2010</b> , 396, 1295-309		105
194	Impaired mitochondrial trafficking in Huntington's disease. <b>2010</b> , 1802, 62-5		49
193	Mitochondria in Huntington's disease. <b>2010</b> , 1802, 52-61		202
192	Molecular mechanisms and potential therapeutical targets in Huntington's disease. <b>2010</b> , 90, 905-81		616
191	Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 1937-51	5.6	96
190	The aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils. <b>2011</b> , 133, 4558-66		126
189	Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. <b>2011</b> , 17, 475-92		127
188	Molecular biology of Huntington's disease. <b>2011</b> , 100, 25-81		15
187	Secondary structures of native and pathogenic huntingtin N-terminal fragments. <b>2011</b> , 115, 11597-608		30
186	Visualization of cell-to-cell transmission of mutant huntingtin oligomers. <b>2011</b> , 3, RRN1210		60
185	Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy. <b>2011</b> , 53, 275-84		43
184	Huntington's Disease and Striatal Signaling. <b>2011</b> , 5, 55		25
183	Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. <i>PLoS ONE</i> , <b>2011</b> , 6, e29199	3-7	49
182	Huntington's disease: from molecular pathogenesis to clinical treatment. <b>2011</b> , 10, 83-98		1101
181	Conformations of the Huntingtin N-term in aqueous solution from atomistic simulations. <b>2011</b> , 585, 3086-9		20

180	Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. <b>2011</b> , 159, 14-23		89
179	Protein folding stress in neurodegenerative diseases: a glimpse into the ER. <b>2011</b> , 23, 239-52		183
178	Huntington's disease, calcium, and mitochondria. <b>2011</b> , 37, 206-18		34
177	Assessment of the efficacy of solutes from extremophiles on protein aggregation in cell models of Huntington's and Parkinson's diseases. <b>2011</b> , 36, 1005-11		4
176	Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates. <b>2011</b> , 54, 342-50		4
175	Conformational diseases: structural studies of aggregation of polyglutamine proteins. <b>2011</b> , 7, 23-43		15
174	KeyPathwayMiner: Detecting Case-Specific Biological Pathways Using Expression Data. <b>2011</b> , 7, 299-313		38
173	Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. <b>2011</b> , 11, 1-12		94
172	Huntington's disease: flipping a switch on huntingtin. <b>2011</b> , 7, 412-4		15
171	Mass spectrometric identification of novel lysine acetylation sites in huntingtin. <b>2011</b> , 10, M111.009829		27
170	The role of ER stress-induced apoptosis in neurodegeneration. <b>2012</b> , 9, 373-87		57
169	Structural features and domain organization of huntingtin fibrils. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 31739-46	5-4	68
168	Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. <b>2012</b> , 109, 3528-33		114
167	CCG polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with Huntington's disease in mainland Chinese families. <b>2012</b> , 312, 92-6		10
166	Shaping the role of mitochondria in the pathogenesis of Huntington's disease. <i>EMBO Journal</i> , <b>2012</b> , 31, 1853-64	13	110
165	Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q. <b>2011</b> , 23, 13-28		13
164	Deletion of the huntingtin proline-rich region does not significantly affect normal huntingtin function in mice. <i>Journal of Huntington's Disease</i> , <b>2012</b> , 1, 71-87	1.9	19
163	Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. <b>2012</b> , 97, 190-204		48

162	Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting Ehelix-rich oligomeric intermediates. <b>2012</b> , 415, 900-17		66
161	Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. <b>2012</b> , 421, 466-90		138
160	Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. <b>2012</b> , 1822, 101-10		108
159	Protein aggregates in Huntington's disease. <b>2012</b> , 238, 1-11		222
158	All-atom stability and oligomerization simulations of polyglutamine nanotubes with and without the 17-amino-acid N-terminal fragment of the Huntingtin protein. <b>2012</b> , 116, 12168-79		11
157	Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. <b>2012</b> , 424, 1-14		64
156	Polyglutamine repeats are associated to specific sequence biases that are conserved among eukaryotes. <i>PLoS ONE</i> , <b>2012</b> , 7, e30824	3-7	21
155	Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties. <i>Biochemistry</i> , <b>2012</b> , 51, 2706-16	3-2	57
154	Intrabodies as neuroprotective therapeutics. <b>2013</b> , 10, 447-58		26
153	Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. <b>2013</b> , 280, 4382-94		44
152	Discovery of a Novel Aggregation Domain in the Huntingtin Protein: Implications for the Mechanisms of Htt Aggregation and Toxicity. <b>2013</b> , 125, 590-595		
151	Discovery of a novel aggregation domain in the huntingtin protein: implications for the mechanisms of Htt aggregation and toxicity. <b>2013</b> , 52, 562-7		9
150	Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach. <b>2013</b> , 105, 699-710		80
149	SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. <b>2013</b> , 4, 362-75		68
148	Neuronal Ca(2+) dyshomeostasis in Huntington disease. <b>2013</b> , 7, 76-84		34
147	Potential for therapeutic manipulation of the UPR in disease. <b>2013</b> , 35, 351-73		62
146	Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. <b>2013</b> , 587, 1997-2007		26
145	Membrane interactions of the amphipathic amino terminus of huntingtin. <i>Biochemistry</i> , <b>2013</b> , 52, 847-583.2		68

144	nNOS(+) striatal neurons, a subpopulation spared in Huntington's Disease, possess functional NMDA receptors but fail to generate mitochondrial ROS in response to an excitotoxic challenge. <b>2013</b> , 4, 112		16
143	An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 6063-71	5.4	55
142	A flexible polyglutamine hinge opens new doors for understanding huntingtin function. <b>2013</b> , 110, 14516-7		7
141	The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 14993-5005	5.4	63
140	The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilia export signal. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 1383-94	5.6	90
139	Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. <b>2013</b> , 110, 14610-5		106
138	Circadian dysfunction in response to <i>in vivo</i> treatment with the mitochondrial toxin 3-nitropropionic acid. <b>2014</b> , 6, e00133		7
137	Huntingtin interactions with membrane phospholipids: strategic targets for therapeutic intervention?. <i>Journal of Huntingtons Disease</i> , <b>2013</b> , 2, 239-50	1.9	27
136	Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington's disease. <b>2013</b> , 6, 42		32
135	Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink-parkin pathway. <b>2014</b> , 6, 18		47
134	Mutant huntingtin replaces Gab1 and interacts with C-terminal SH3 domain of growth factor receptor binding protein 2 (Grb2). <b>2014</b> , 87, 77-83		7
133	Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. <b>2014</b> , 4, 91-122		34
132	A mitochondrial basis for Huntington's disease: therapeutic prospects. <b>2014</b> , 389, 277-91		14
131	Atomistic mechanisms of huntingtin N-terminal fragment insertion on a phospholipid bilayer revealed by molecular dynamics simulations. <b>2014</b> , 82, 1409-27		10
130	Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease. <b>2014</b> , 2, 86		11
129	Investigation of membrane penetration depth and interactions of the amino-terminal domain of huntingtin: refined analysis by tryptophan fluorescence measurement. <b>2014</b> , 43, 347-60		15
128	Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime. <b>2014</b> , 50, 107-18		29
127	Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 2324-38	5.6	24

126	Polyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance. <i>Biochemistry</i> , <b>2014</b> , 53, 6653-66	3.2	51
125	Neurotoxicity in Huntington Disease. <b>2014</b> , 1511-1524		
124	Genetic modifiers of obesity and bariatric surgery outcomes. <b>2014</b> , 23, 43-8		14
123	Inhibition of mitochondrial protein import by mutant huntingtin. <b>2014</b> , 17, 822-31		139
122	Curvature enhances binding and aggregation of huntingtin at lipid membranes. <i>Biochemistry</i> , <b>2014</b> , 53, 2355-65	3.2	32
121	One-pot semisynthesis of exon 1 of the Huntingtin protein: new tools for elucidating the role of posttranslational modifications in the pathogenesis of Huntington's disease. <b>2014</b> , 53, 1928-33		39
120	One-Pot Semisynthesis of Exon 1 of the Huntingtin Protein: New Tools for Elucidating the Role of Posttranslational Modifications in the Pathogenesis of Huntington's Disease. <b>2014</b> , 126, 1959-1964		5
119	The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model. <b>2015</b> , 10, 67		32
118	Altered lysosomal positioning affects lysosomal functions in a cellular model of Huntington's disease. <b>2015</b> , 42, 1941-51		33
117	Cell Therapy in Huntington's Disease. <b>2015</b> ,		0
116	N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. <b>2015</b> , 85, 726-41		48
115	Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregation. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 2560-76	5.4	60
114	The emerging role of the first 17 amino acids of huntingtin in Huntington's disease. <b>2015</b> , 6, 33-46		41
113	Primary cilia and autophagic dysfunction in Huntington's disease. <b>2015</b> , 22, 1413-24		20
112	Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations. <b>2015</b> , 108, 1187-98		16
111	Huntington disease. <b>2015</b> , 1, 15005		672
110	Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. <b>2015</b> , 138, 3632-53		31
109	Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion. <b>2015</b> , 14, 1241-53		25



108	Enhanced molecular mobility of ordinarily structured regions drives polyglutamine disease. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 24190-200	5.4	18
107	Fundamentals of Neurodegeneration and Protein Misfolding Disorders. <b>2015</b> ,		3
106	Chaperone protein HYPK interacts with the first 17 amino acid region of Huntingtin and modulates mutant HTT-mediated aggregation and cytotoxicity. <b>2015</b> , 456, 66-73		21
105	A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 450-62	5.6	27
104	Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts. <b>2015</b> , 51, 331-48		51
103	Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?. <b>2015</b> , 52, 1297-1314		39
102	Investigating Mutations to Reduce Huntingtin Aggregation by Increasing Htt-N-Terminal Stability and Weakening Interactions with PolyQ Domain. <b>2016</b> , 2016, 6247867		4
101	Altered Co-Translational Processing Plays a Role in Huntington's Pathogenesis-A Hypothesis. <b>2016</b> , 9, 54		4
100	The Genomic Basis of Noise-induced Hearing Loss: A Literature Review Organized by Cellular Pathways. <b>2016</b> , 37, e309-16		15
99	CCT complex restricts neuropathogenic protein aggregation via autophagy. <i>Nature Communications</i> , <b>2016</b> , 7, 13821	17.4	65
98	The Biology of Huntingtin. <b>2016</b> , 89, 910-26		450
97	Immunotherapy and Biomarkers in Neurodegenerative Disorders. <b>2016</b> ,		3
96	Huntingtin N17 domain is a reactive oxygen species sensor regulating huntingtin phosphorylation and localization. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 3937-3945	5.6	36
95	Immunotherapy on Experimental Models for Huntington's Disease. <b>2016</b> , 139-150		1
94	Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding. <b>2016</b> , 111, 349-362		36
93	Mitochondrial Dysfunction in Neurodegenerative Disorders. <b>2016</b> ,		2
92	Characterization of axonal transport defects in Drosophila Huntingtin mutants. <b>2016</b> , 30, 212-221		16
91	Protein Misfolding and Aggregation: Implications for Mitochondrial Dysfunction and Neurodegeneration. <b>2016</b> , 241-253		1

90	Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling. <b>2016</b> , 53, 2944-2953		36
89	Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution. <b>2016</b> , 110, 1075-88		11
88	Huntington's Disease: Relationship Between Phenotype and Genotype. <b>2017</b> , 54, 342-348		21
87	Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective. <b>2017</b> , 139, 1168-1176		40
86	Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion. <i>Journal of Huntingtons Disease</i> , <b>2017</b> , 6, 47-62	1.9	8
85	Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01. <b>2017</b> , 139, 5640-5643		34
84	Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment. <b>2017</b> , 121, 4713-4721		9
83	Interaction of misfolded proteins and mitochondria in neurodegenerative disorders. <b>2017</b> , 45, 1025-1033		50
82	Structural perturbations on huntingtin N17 domain during its folding on 2D-nanomaterials. <b>2017</b> , 28, 354001		8
81	Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity. <i>Human Molecular Genetics</i> , <b>2017</b> , 26, 3763-3775	5.6	20
80	Mitochondrial Ca handling in Huntington's and Alzheimer's diseases - Role of ER-mitochondria crosstalk. <b>2017</b> , 483, 1069-1077		25
79	Energy defects in Huntington's disease: Why "in vivo" evidence matters. <b>2017</b> , 483, 1084-1095		44
78	Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch. <b>2017</b> , 11, 145		28
77	Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. <b>2017</b> , 144, 15-28		9
76	Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1. <b>2018</b> , 24, 129-140		1
75	N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 18540-18558	5.4	36
74	A Mitochondria-Associated Oxidative Stress Perspective on Huntington's Disease. <b>2018</b> , 11, 329		48
73	Mitochondrial degradation of amyloidogenic proteins - A new perspective for neurodegenerative diseases. <b>2019</b> , 181, 101660		12

72	Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23. <b>2019</b> , 116, 16593-16602	34
71	Discovery of Arginine Ethyl Ester as Polyglutamine Aggregation Inhibitor: Conformational Transitioning of Huntingtin N-Terminus Augments Aggregation Suppression. <b>2019</b> , 10, 3969-3985	5
70	The Role of Post-translational Modifications on the Energy Landscape of Huntingtin N-Terminus. <b>2019</b> , 6, 95	10
69	Structure of Membrane-Bound Huntingtin Exon 1 Reveals Membrane Interaction and Aggregation Mechanisms. <b>2019</b> , 27, 1570-1580.e4	11
68	Conformational studies of pathogenic expanded polyglutamine protein deposits from Huntington's disease. <b>2019</b> , 244, 1584-1595	9
67	Huntingtin's N-Terminus Rearrangements in the Presence of Membranes: A Joint Spectroscopic and Computational Perspective. <b>2019</b> , 10, 472-481	8
66	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. <b>2019</b> , 30, 1450-1499	50
65	Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. <b>2020</b> , 134, 104619	26
64	Investigating the interactions of the first 17 amino acid residues of Huntingtin with lipid vesicles using mass spectrometry and molecular dynamics. <b>2020</b> , 55, e4470	4
63	Phosphomimetic Mutations Impact Huntingtin Aggregation in the Presence of a Variety of Lipid Systems. <i>Biochemistry</i> , <b>2020</b> , 59, 4681-4693	3.2 0
62	Implications of the Orb2 Amyloid Structure in Huntington's Disease. <b>2020</b> , 21,	1
61	Mutant huntingtin does not cross the mitochondrial outer membrane. <i>Human Molecular Genetics</i> , <b>2020</b> , 29, 2962-2975	5.6 2
60	Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases. <b>2020</b> , 12,	6
59	Structural and functional features of medium spiny neurons in the BACHD $\Delta$ 17 mouse model of Huntington's Disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234394	3.7 2
58	The Inverse Comorbidity between Oncological Diseases and Huntington's Disease: Review of Epidemiological and Biological Evidence. <b>2020</b> , 56, 269-279	1
57	Serine residues 13 and 16 are key modulators of mutant huntingtin induced toxicity in <i>Drosophila</i> . <b>2021</b> , 338, 113463	2
56	Lipid headgroups alter huntingtin aggregation on membranes. <b>2021</b> , 1863, 183497	4
55	Site-Specific Phosphorylation of Huntingtin Exon 1 Recombinant Proteins Enabled by the Discovery of Novel Kinases. <b>2021</b> , 22, 217-231	8

54	The Nt17 domain and its helical conformation regulate the aggregation, cellular properties and neurotoxicity of mutant huntingtin exon 1.	3
53	Normalization of Calcium Balance in Striatal Neurons in Huntington's Disease: Sigma 1 Receptor as a Potential Target for Therapy. <b>2021</b> , 86, 471-479	0
52	 <a href="#">10.1016/j.jneurosci.2021.08.033</a> <b>2021</b> , 86, 554-563	
51	Membrane Interactions Accelerate the Self-Aggregation of Huntingtin Exon 1 Fragments in a Polyglutamine Length-Dependent Manner. <b>2021</b> , 22,	0
50	Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics. <b>2021</b> , 58, 6350-6377	4
49	Mitochondrial membranes modify mutant huntingtin aggregation. <b>2021</b> , 1863, 183663	2
48	The Nt17 Domain and its Helical Conformation Regulate the Aggregation, Cellular Properties and Neurotoxicity of Mutant Huntingtin Exon 1. <b>2021</b> , 433, 167222	2
47	Huntington's Disease. <b>2010</b> , 45-63	38
46	Polyglutamine aggregation in Huntington and related diseases. <b>2012</b> , 769, 125-40	11
45	Exploiting yeast genetics to inform therapeutic strategies for Huntington's disease. <b>2009</b> , 548, 161-74	13
44	Detecting Disease-Specific Dysregulated Pathways Via Analysis of Clinical Expression Profiles. <b>2008</b> , 347-359	34
43	Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. <i>Nature Communications</i> , <b>2020</b> , 11, 2582	17.4 15
42	Site-specific phosphorylation of Huntingtin exon 1 recombinant proteins enabled by the discovery of novel kinases.	0
41	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.	5
40	N-terminal phosphorylation of Huntingtin: A molecular switch for regulating Htt aggregation, helical conformation, internalization and nuclear targeting.	1
39	TBK1 regulates autophagic clearance of soluble mutant huntingtin and inhibits aggregation/toxicity in different models of Huntington's disease.	0
38	Robust de novo pathway enrichment with KeyPathwayMiner 5. <b>2016</b> , 5, 1531	23
37	Dysfunctional mitochondrial respiration in the striatum of the Huntington's disease transgenic R6/2 mouse model. <b>2013</b> , 5,	20

36	Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. <i>PLoS ONE</i> , <b>2009</b> , 4, e5727	3-7	49
35	Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. <i>PLoS ONE</i> , <b>2010</b> , 5, e8905	3-7	55
34	F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics. <i>PLoS ONE</i> , <b>2010</b> , 5, e9053	3-7	26
33	Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. <i>PLoS ONE</i> , <b>2011</b> , 6, e16676	3-7	25
32	Huntingtin is critical both pre- and postsynaptically for long-term learning-related synaptic plasticity in Aplysia. <i>PLoS ONE</i> , <b>2014</b> , 9, e103004	3-7	15
31	Huntingtin Subcellular Localisation Is Regulated by Kinase Signalling Activity in the StHdhQ111 Model of HD. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144864	3-7	3
30	TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models. <i>EMBO Journal</i> , <b>2020</b> , 39, e104671	13	15
29	Threonine 3 regulates Serine 13/16 phosphorylation in the huntingtin exon 1. <i>Matters Select</i> ,	1	2
28	Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington's Disease. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 5137-5158	4-3	3
27	Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract. <i>ELife</i> , <b>2016</b> , 5,	8,9	41
26	The interplay between the chaperonin TRiC and N-terminal region of Huntingtin mediates Huntington's Disease aggregation and pathogenesis. <i>Research and Perspectives in Alzheimer's Disease</i> , <b>2013</b> , 121-132		
25	Mitochondrial Dysfunction in Brain and Muscle Pathology of Huntington's Disease. <b>2014</b> , 3097-3116		
24	Gene Therapy for Huntington's Disease. <i>Neuromethods</i> , <b>2015</b> , 121-151	0.4	
23	Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity.		
22	Huntington's Disease and Other Polyglutamine Repeat Diseases: Molecular Mechanisms and Pathogenic Pathways. <b>2018</b> , 145-188		
21	Post-translational Modifications: A Mystery to Unravel Huntington's Disease Prognosis. <b>2019</b> , 311-334		
20	Membrane interactions accelerate the self-aggregation of huntingtin exon 1 fragments in a polyglutamine length-dependent manner.		
19	N-alpha-acetylation of Huntingtin protein increases its propensity to aggregate. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 297, 101363	5-4	0

18	Huntington's Disease: Calcium Dyshomeostasis and Pathology Models. <i>Acta Naturae</i> , <b>2017</b> , 9, 34-46	2.1	10
17	Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: An opinion. <i>EXCLI Journal</i> , <b>2021</b> , 20, 1086-1090	2.4	1
16	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. <i>Nature Communications</i> , <b>2021</b> , 12, 6579	17.4	4
15	The amyloid state of proteins: A boon or bane?. <i>International Journal of Biological Macromolecules</i> , <b>2022</b> , 200, 593-617	7.9	0
14	Endoplasmic reticulum-mitochondria signaling in neurons and neurodegenerative diseases.. <i>Journal of Cell Science</i> , <b>2022</b> , 135,	5.3	4
13	CryoET Reveals Organelle Phenotypes in Huntington Disease Patient iPSC-Derived and Mouse Primary Neurons.		
12	Presentation_1.pdf. <b>2019</b> ,		
11	Molecular Pathophysiological Mechanisms in Huntington's Disease. <i>Biomedicine</i> , <b>2022</b> , 10, 1432	4.8	2
10	Oxidation Promotes Distinct Huntingtin Aggregates in the Presence and Absence of Membranes. <i>Biochemistry</i> , <b>2022</b> , 61, 1517-1530	3.2	
9	Possible Co-Evolution of Polyglutamine and Polyproline in Huntingtin Protein: Proline-Rich Domain as Transient Folding Chaperone. <i>Journal of Physical Chemistry Letters</i> , <b>2022</b> , 13, 6331-6341	6.4	0
8	Huntingtin and Its Partner Huntingtin-Associated Protein 40: Structural and Functional Considerations in Health and Disease. <i>Journal of Huntingtons Disease</i> , <b>2022</b> , 1-16	1.9	
7	Neurotoxicity in Huntington Disease. <b>2022</b> , 1-17		0
6	HSF1 and Its Role in Huntington's Disease Pathology. <b>2022</b> ,		0
5	BDNF and TRiC-inspired Reagents Rescue Cortical Synaptic Deficits in a Mouse Model of Huntington's Disease.		0
4	CryoET reveals organelle phenotypes in huntington disease patient iPSC-derived and mouse primary neurons. <b>2023</b> , 14,		0
3	Neurotoxicity in Huntington Disease. <b>2022</b> , 1747-1763		0
2	Mechanistic Insight into the Suppression of Polyglutamine Aggregation by SRCP1. <b>2023</b> , 18, 549-560		0
1	The structure of pathogenic huntingtin exon 1 defines the bases of its aggregation propensity. <b>2023</b> , 30, 309-320		0

